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Abstract
The essential biological role of erythropoietin (EPO) in maintaining erythrocyte mass has been
well understood for many years. Although EPO is required for the maturation of red cells, it also
has strong procoagulant effects on the vascular endothelium and platelets, which limit erythrocyte
losses after hemorrhage. Like other members of the type 1 cytokine superfamily, EPO has multiple
biological activities. For the past 10 years, multiple investigators have shown that EPO acts as a
locally produced antagonist of proinflammatory cytokines that are generated by the innate immune
response in response to infection, trauma, or metabolic stress. Specifically, EPO inhibits apoptosis
of cells surrounding a locus of injury, reduces the influx of inflammatory cells, and recruits tissue-
specific stem cells and endothelial progenitor cells. Available evidence suggests that these
multiple, nonerythropoietic effects of EPO are mediated by a tissue protective receptor (TPR) that
is distinct from the homodimeric receptor responsible for erythropoiesis. Notably, activation of the
TPR requires a higher concentration of EPO than is needed for maximal erythropoiesis.
Unfortunately, these higher concentrations of EPO also stimulate hematopoietic and pro-coagulant
pathways, which can cause adverse effects and, therefore, potentially limit the clinical use of EPO
for tissue protection. To circumvent these problems, the EPO molecule has been successfully
modified in a variety of ways to interact only with the TPR. Early clinical experience has shown
that these compounds appear to be safe, and proof of concept trials are ready to begin.
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OVERVIEW: TISSUE PROTECTIVE EFFECTS OF ERYTHROPOIETIN
Erythropoietin (EPO) was first identified as a hormone that stimulates erythropoiesis by
blocking the programmed cell death of red cell precursors (reviewed by Fisher1). In its
endocrine role, EPO is produced in the adult kidney in response to hypoxia and released into
the circulation. After binding to the homodimeric EPO receptor (EPOR)2 at picomolar
concentrations, it facilitates the survival of proerythroblasts within the bone marrow (Fig. 1).
Because erythrocyte precursors are continuously produced, a sustained, low concentration of
EPO within the circulation is required to replace senescent red cells.
Reprints: Michael Brines, MD, PhD, Warren Pharmaceuticals, 712 Kitchawan Rd, Ossining, NY 10562.
mbrines@warrenpharma.com.
C.C.H. is on the Scientific Advisory Board and owns stock in Warren Pharmaceuticals, which is pursuing the clinical development
tissue protective cytokines and peptides.
M.B. is a director and shareholder of Warren Pharmaceuticals.
NIH Public Access
Author Manuscript
J Investig Med. Author manuscript; available in PMC 2012 October 1.
Published in final edited form as:













Unexpectedly, in 1990, investigators observed that EPO also stimulated growth and
migration of endothelial cells in culture.2 Notably, the concentrations of EPO required for
these effects were substantially higher (nanomolar) than that required for erythropoiesis.
Follow-on studies showed neuronal-like PC12 cells also expressed a receptor for EPO with a
lower affinity for EPO3 that was biochemically distinct from the (EPOR)2. Avariety of
recent evidence has shown that this alternative receptor for EPO is a heteromer, composed
of EPOR monomer subunits and the beta common receptor (CD131) that is also used for
signaling by the type I cytokines granulocyte macrophage colony-stimulating factor,
interleukin 3 (IL-3), and IL-5.4 Recently, Sautina et al.5 have proposed that the VEGF
receptor also associates with CD131 in vascular endothelial cells.
The existence of receptor isoforms suggested that the EPO has other biological functions in
addition to erythropoiesis. Indeed, for the past decade, additional work has shown that EPO
is a principal component of a paracrine-autocrine system that mediates tissue protection. In
this mode, EPO is locally produced in response to tissue injury but with a significant time
delay. This pool of EPO subsequently signals through the heteromeric receptor (tissue
protective receptor; TPR) to prevent secondary injury by suppressing proinflammatory
cytokines activated by the innate immune response and blocks cellular apoptosis. In a
variety of tissues,6,7 EPO antagonizes both the production and the effects of
proinflammatory cytokines and limits ischemia-reperfusion injury. Expression of the TPR
peaks several hours after infection or injury but before EPO production. In addition,
proinflammatory cytokines suppress endogenous EPO but stimulate TPR expression. It is
the relative excess of the TPR with respect to EPO that provides the rationale for
administration of exogenous EPO for tissue protection.
Historically, the cytoprotective effects of EPO were first demonstrated in the nervous
system, which remains the most extensively studied tissue to date. Our group expanded
relevance of the newly discovered neuroprotective effects of EPO into ischemic, traumatic,
and inflammatory lesions in a series of publications8 beginning in 2000 and as reviewed by
Brines and Cerami.6 Furthermore, we showed that systemically administered EPO could
cross the blood-brain barrier (BBB) in therapeutically relevant concentrations and
significantly reduce the volume of injury in animal models of stroke or traumatic brain
injury (TBI). The discovery that EPO passes through the intact BBB and is active not only in
ischemia but in a variety of injury models greatly accelerated interest in using recombinant
human EPO (rhEPO) to prevent brain injury. Since then, we and many other investigators
have shown that EPO possesses tissue protective effects in diverse tissues and organs,
including the heart, kidney, gut, lung, and skin (reviewed by Arcasoy9). Here, we will
highlight in moderate detail some of the significant findings in the nervous system as
examples of EPO-mediated tissue protection.
ERYTHROPOIETIN IN CENTRAL AND PERIPHERAL NERVOUS SYSTEM
INJURIES
Stroke
Many laboratories have assessed the effects of systemically administered rhEPO in animal
models of nonhemorrhagic ischemic stroke. Recently, 2 meta-analyses of these animal
studies were published. Minnerup et al.10 analyzed 16 preclinical studies and concluded that
when rhEPOs (or its analogues, as discussed later) were administered after the onset of
ischemia, infarct size was reduced by about one-third and was associated with improved
neurobehavioral outcomes. A second meta-analysis11 examined 19 studies involving 346
animals for infarct size and 425 animals for neurobehavioral outcome and found that rhEPO
improved infarct size by 30.0% (95% confidence interval [CI], 21.3–38.8) and
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neurobehavioral outcome by 39.8% (33.7–45.9). These authors also note that studies that
randomized the animals to treatment group or that blinded assessment of outcome showed
lower efficacy.11
Results of the first attempt to translate these preclinical findings into a patient population
suffering from nonhemorrhagic stroke in the territory of the middle cerebral artery suggested
that rhEPO might be beneficial for the treatment of patients.12 However, a larger double-
blind, placebo-controlled, randomized multicenter EPO Stroke Trial (NCT00604630),
designed to evaluate efficacy and safety of rhEPO in stroke, did not demonstrate a
therapeutic effect. In fact, the overall death rate was increased in the rhEPO-treated group:
16.4% (n = 42 of 256) versus 9.0% (n = 24 of 266) in the placebo group (odds ratio, 1.98;
95% CI, 1.16–3.38; P = 0.01).13 The major difference between these 2 studies was that the
later one included a significant number of patients that also received thrombolytic treatment.
Results of a recent preclinical rodent stroke model provide a plausible explanation for the
different outcome of these trials: Zechariah et al.14 have shown that tissue plasminogen
activator amplifies EPO-mediated metalloproteinase production, leading to a breakdown of
the BBB and increased tissue damage.
Traumatic Brain and Spinal Cord Injury
In experimental models, rhEPO improves outcome after a TBI.8,15,16 At high doses, rhEPO
has been shown to have neuroprotective effects when given early after injury and to have
effects that enhance neurological recovery even when given with a significant temporal
delay.17–23 The time window for EPO-induced neuroprotection has not been well defined,
but EPO given as long as 24 hours post-injury has been reported to have significantly
enhanced neurological recovery in TBI models. A clinical trial evaluating the effects of
rhEPO in patients with TBI (NCT00313716) is ongoing at the Baylor College of Medicine
and the University of Texas Health Science Center at Houston/Memorial Hermann Hospital.
An additional multicenter trial is planned, but not yet initiated, by the Australian and New
Zealand Intensive Care Research Centre (NCT00987454). Multiple laboratories have also
demonstrated that rhEPO is neuroprotective after spinal cord injury in animal models.18–23
There is one active trial (NCT00561067) evaluating the efficacy of rhEPO in patients with
traumatic spinal cord injury.
Cerebral Malaria
Cerebral malaria (CM) is a devastating neurological syndrome arising from an extreme
production of proinflammatory cytokines in response to parasite-infected erythrocytes
within the brain vasculature. Two laboratories have demonstrated the protective effect of
rhEPO in murine models of CM.24,25 The importance of endogenous EPO in human CM is
underscored by a recent clinical study of 124 Kenyan children with CM, in which high
endogenous plasma levels of EPO correlated with an 80% reduction in risk of developing
neurological sequelae.26 A clinical trial evaluating the use of rhEPO as an adjunct treatment
for children with CM is currently active. This study (NCT00697164) aims to enroll 200
children of 6 months to 14 years of age admitted to the hospital with CM but without severe
anemia or pulmonary involvement. The children will be treated with standard antimalarial
treatment (quinine) and a 3-day course of high-dose rhEPO. The main endpoint of this trial
is survival at 5 days after admission, and the study is powered to detect a 25% reduction of
mortality.
Hypoxic-Ischemic Encephalopathy
Recombinant human EPO confers neuronal protection when administered systemically to
animals subjected to global brain ischemia. A trial of rhEPO treatment for 153 term infants
with moderate hypoxic-ischemic encephalopathy observed a reduced disability.27 Death or
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moderate/severe disability occurred in 35 (43.8%) of 80 infants in the control group and 18
(24.6%) of 73 infants in the EPO group (P = 0.017) at 18 months. In addition, a
retrospective study of 82 preterm infants given 6 weeks of rhEPO therapy to prevent anemia
identified an association between rhEPO doses and higher scores on the Bayley Scale of
Infant Development, Psychomotor Developmental, and Mental Developmental Index at 12
months of age.28
Many additional in vivo and in vitro models of nervous system injury have been evaluated
including diabetic or toxic neuropathies, experimental autoimmune encephalitis,29–31 and
subarachnoid hemorrhage32,33 as recently reviewed by Brines and Cerami.6 A small number
of pilot clinical studies have also been performed in normal volunteers and in patients with
depression that show effects of EPO on cognition and mood34,35 or in patients with
schizophrenia,36 amyotrophic lateral sclerosis,37 or multiple sclerosis.38
MANY TISSUES EXPRESS EPO IN RESPONSE TO INJURY
The role of EPO as a modulator of the innate immune response is not limited to the nervous
system. Virtually, all tissues examined to date respond to metabolic stress or injury by
activating a local EPO response.
Myocardial Injury
The heart was the first tissue outside of the brain for which cytoprotective effects of EPO
were confirmed.39 Subsequent work performed by numerous investigators showed that
similar to the effects within the nervous system, rhEPO protects the myocardium from
ischemic, infectious, traumatic, or toxic injuries.40–45 Endogenous EPO is produced locally
by myocardial tissue, and as expected of a paracrine/autocrine system, a receptor for EPO is
expressed by neonatal and adult rat cardiomyocytes,46,47 ventricular myocytes, and
endothelial cells.48 Preclinical studies have shown that administration of rhEPO after
ischemia/reperfusion decreases infarct size in part by inhibiting cardiomyocyte apotosis.
Recombinant human EPO and endogenous EPO may also reduce subacute ischemia by
inducing neovascularization, either by stimulating endothelial cells in situ or by mobilizing
endothelial progenitor cells from the bone marrow.
Clinical studies have demonstrated a beneficial effect of rhEPO administration in patients
with chronic heart failure. Unlike patient populations with chronic kidney disease and
cancer-related anemia (discussed later), treatment with erythropoiesis-stimulating agents
(ESAs) has not been associated with higher mortality rates in patients with chronic heart
failure. In fact, a recent meta-analysis of 7 randomized controlled clinical trials with 650
patients (363 and 287 patients treated with ESAs and placebo, respectively) showed a
decreased risk of hospitalization for heart failure in the ESA-treated group and no difference
in mortality between the 2 groups.49 Although one clinical study has demonstrated that
rhEPO improved cardiac function without increasing hematocrit,50 in most, it has been
impossible to determine if these beneficial effects on the human cardiovascular system occur
independently of increases in hemoglobin levels.
In addition, in contrast to trials in which ESAs were administered chronically, acute dosing
has been evaluated in the setting of revascularization procedures after myocardial infarction.
Several small studies have been published that present opposite results. Binbrek et al.51
observed no protective effect of EPO when used in the setting of thrombolysis. In contrast,
when administered after stent placement, EPO was observed to confer benefit by reducing
infarct size.52
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It is important to appreciate that a number of observations derived from animal studies
suggest that EPO’s cardioprotective properties are independent of its erythropoietic
activities. First, a single dose of rhEPO that does not increase the hematocrit is protective in
rodent39 and rabbit53 models of cardiac infarction. Second, isolated cardiomyocytes and
isolated perfused hearts are more tolerant to hypoxia when treated with rhEPO.39 Third,
EPO modified to possess no erythropoietic activity (discussed later) retains its
cardioprotective properties in permanent ischemia and ischemia/reperfusion.54 Fourth, EPO
is not protective for cardiomyocytes subjected to metabolic stress that have been obtained
from βCR (CD131) knockout mice that possess a fully intact (EPOR)2.4
HOW DOES EPO PROTECT TISSUES?
Erythropoietin’s mechanisms of protective action have been most extensively evaluated in
nervous tissue for which rhEPO has been shown to possess neurotrophic,55 antiapoptotic,
and angiogenic properties56 and to promote neural regeneration.57 These effects are dose
dependent58 and, in some cases, depend in part on other known molecules, for example,
brain-derived nerve growth factor.59 In animal models, the expression of EPO and EPOR in
the brain after cerebral ischemia/infarction occurs with a strict temporal sequence.
Histopathological changes identify a pneumbra around the lesion, that is, tissue at risk for
further injury. Within the penumbra, endothelial cells, intravascular inflammatory cells, and
neurons all express EPO, whereas EPOR is expressed by neurons, astrocytes, and
endothelial cells.57,60,61 Because the expression of EPOR precedes the up-regulation of
EPO synthesis,60 tissue sensitivity to EPO increases as a function of time.62 Also, EPO can
increase cerebral blood flow by its effect on endothelial nitric oxide production63 and by
preventing endothelial cell apoptosis and, in these ways, maintain the microcirculation
within the penumbra. In the subacute phase, EPO can also improve tissue oxygenation by
driving neoangiogenesis. These all tend to reduce infarct volume significantly.57,60,61 The
persistent up-regulation of EPO production by astrocytes after hypoxia also provides rapidly
available sources of EPO to enable neurons to tolerate otherwise damaging ischemia.61
Erythropoietin also strongly prevents the development of tissue edema by modulating the
water transporter aquaporin in astrocytes.64
Receptor Signaling Cascade
Erythropoiesis occurs when EPO binds to the preformed (EPOR)2 and causes a
conformational change that subsequently triggers Janus kinase/signal transducers and
activators of transcription (STAT) activation. The resulting molecular cascade results in the
up-regulation of antiapoptotic proteins (eg, Bcl-2) that inhibit apoptosis of erythrocyte
precursors.65 In contrast, EPO-mediated tissue protection uses multiple signaling pathways
activated in parallel and that vary by cell and tissue type. Cell signaling pathways that are
known to be used by EPO and mediate tissue protection include (1) phosphorylation and
activation of Janus kinase1/2, STAT3, or STAT5A (but not of STAT1alpha and STAT5B);
(2) phosphorylation and activation of phosphoinositol 3-kinase and its downstream kinase
Akt; (3) activation of protein kinase C, which results in a rise in free intra-cellular calcium;
(4) RAS/mitogen-activated protein kinase (Raf, MEK1/2, p42/44 MAPK, and p38 MAPK);
and (5) up-regulation of Sonic hedgehog and its downstream target mammalian achaetescute
homolog 1 (Mash1).66
Individual specific tissue protective effects that are activated by EPO in particular cell types
can depend upon different pathways. For example, EPO has both neurotrophic and
antiapoptotic effects in neurons. For hippocampal neurons, EPO signals via both the PI3K/
Akt and the STAT pathways to support neurite outgrowth, whereas the STAT pathway is not
required for inhibition of apoptosis.67 In contrast, in the SH-SY5Y differentiated
Hand and Brines Page 5













neuroblastoma cell line, both the Akt and STAT pathway activation is required to prevent
apoptosis.68
A CONUNDRUM: THE HIGH DOSES OF RHEPO REQUIRED FOR TISSUE
PROTECTION CAN CAUSE SERIOUS ADVERSE EFFECTS
Despite the many attractive features of rhEPO-mediated tissue protection observed in
preclinical models, translation of rhEPO-dependent protection into the clinical setting for
use in neurological, renal, or cardiac disorders has posed a dilemma. The high doses of
rhEPO required for tissue protection and enhancement of recovery are associated with very
real risks of significant clinical complications. In fact, even moderate doses of rhEPO
administered chronically have been associated with adverse consequences in patients. For
example, the very large Trial to Reduce Cardiovascular Events with Aranesp Therapy trial69
evaluated whether the use of an ESA to treat anemia in diabetic patients with renal
insufficiency could reduce mortality and slow disease progression. In fact, the results
showed an increased incidence of stroke within the ESA arm and no beneficial effects of
rhEPO on disease progression.
Survival
Large-scale clinical studies involving higher doses of ESAs administered as treatment of
anemia or to improve quality of life have shown that as a class ESAs reduce overall survival
and/or increase the risk of tumor progression or recurrence in patients with breast, non-small
cell lung, head and neck, lymphoid, and cervical cancer
(http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm). A recent meta-
analysis of randomized trials evaluating the association of recombinant ESAs with mortality
in patients with cancer analyzed data from a total of 13,933 patients with cancer in 53 trials.
70 Erythropoiesis-stimulating agents increased mortality during the active study period
(combined hazard ratio [cHR], 1.17; 95% CI, 1.06–1.30) and reduced overall survival (cHR,
1.06; 95% CI, 1.00–1.12), with little heterogeneity between trials. The cHR for mortality
during the active study period was 1.10 (range, 0.98–1.24), whereas it was 1.04 (range,
0.97–1.11) for overall survival. There was little evidence for a difference between trials of
patients given different anticancer treatments (P value for interaction = 0.42). The
mechanism by which ESAs affect these outcomes is not entirely clear but appears to arise
from thrombosis and tumor growth.
Thrombosis
Multiple studies using both animal models and patients indicate that ESAs augment
thrombopoeisis as well as platelet and endothelial cell activation.71–77 The resulting
thrombotic complications of EPO are dose related.78–80 Almost all studies of ESAs
administered to critically ill patients and in postoperative patients have shown an increased
risk of thromboembolic events after ESA administration. For example, a randomized,
double-blind, placebo-controlled, multicenter trial (N = 1460) in anemic critically ill patients
demonstrated a 29-day survival benefit in the trauma subgroup receiving rhEPO (mortality,
6.7% vs 3.5%), although it did not result in fewer blood transfusions. Despite the
improvement in the outcome of the rhEPO-treated patients, there was a significant increase
in the incidence of thrombo-phlebitis, from 5.7% to 8.7% (P = 0.04).81 The most serious
complications associated with rhEPO occurred in a recent trial of rhEPO, given at 40,000
IU/d for 3 days after stroke, in which rhEPO-treated patients had a higher rate of intracranial
hemorrhage and a higher mortality rate.13 These results triggered the US Food Drug
Administration to place all rhEPO neuroprotection trials in the United States on hold.
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A second possible mechanism by which exogenously administered rhEPO may worsen
outcome in patients with cancer is by promoting vasculogenesis and tumor growth.
Erythropoietin has been shown to promote physiological angiogenesis,82,83 angiogenesis
during wound healing,84 and estrogen-dependant cyclical angiogenesis in the uterus.85,86
However, it appears that EPO can also drive pathological neoangiogenesis. For example, 3
important studies in different mouse models of cancer have shown that EPO is an important
angiogenic factor that regulates neovascularization of tumors.86–88 An additional concern is
that EPO may act as a growth factor for certain types of cancer cells, although it must be
noted that there is a great deal of controversy concerning this possibility. On the one hand,
results of a number of in vitro studies show that rhEPO can induce proliferation, increase
cellular migration and invasion, as well as confer resistance to chemoradiation in some
tumor cells.89–95 On the other hand, studies using different tumor types have also concluded
that rhEPO does not affect cellular proliferation or in vitro sensitivity to chemotherapeutic
agents.95–97 It is notable that many workers in the field have demonstrated the expression of
EPOR on tumor cells and responses to EPO (reviewed by Arcasoy9). In rebuttal, several
papers recently published by scientists employed by Amgen (the largest manufacturer of
ESAs) have concluded that the reagents used by other scientists are faulty98 and that tumor
cells do not express a functional EPOR or respond biologically to rhEPO.99,100 Further work
will obviously be required to clarify this controversial area.
A SOLUTION TO THESE PROBLEMS: DESIGNER EPOS THAT ARE ONLY
TISSUE PROTECTIVE?
If the erythropoietic effects of EPO could be functionally separated from its tissue protective
effects, more specific ligands could potentially be developed that avoid adverse effects that
depend upon the EPOR homodimer. In 2003–2004, our group demonstrated for the first time
that the hematopoietic and tissue protective effects of EPO are, in fact, independent
biological properties101,102 (Table 1). This was accomplished using 2 approaches: (1) by
capitalizing on the very different temporal characteristics of EPO signaling in erythropoiesis
compared with tissue protection and (2) by preferentially interfering with the binding of
EPO to the hematopoietic receptor.
As discussed earlier, effective erythropoiesis requires EPO to be constantly available. In
contrast, tissue protection is characterized by the appearance of molecules that trigger long-
lasting effects, acting in effect as molecular switches for long-lasting gene expression
programs. Recombinant human EPO possesses a relatively long plasma half-life (~5–8
hours) because of the presence of multiple oligosaccharides terminated by sialic acid.
Removal of these sialic acid residues drastically increases plasma clearance, such that
asialo-EPO has a reduced plasma half-life of only ~2 minutes. Although a single injection of
asialo-EPO has no effect on hematopoiesis, it is as potent as native EPO for tissue
protection.101
Another approach to the development of specific tissue protective ligands involves
considerations of EPO structure-activity relationships with respect to the hematopoietic
receptor. The molecular interaction of EPO with the (EPOR)2 complex has been extensively
studied, and critical regions within EPO that interact (Fig. 2). Erythropoietin with (EPOR)2
have been identified103–106 binds to both subunits of the homodimer and, while in a
bridging position, induces a conformational change that triggers receptor signaling. The
specific regions of EPO involved are portions of helices A and C (site 2, Fig. 2) as well as
helix D and the loop connecting helices A and B (site 1, Fig. 2).103–106 Chemical or
mutational modifications of amino acid residues within these 2 regions of the EPO molecule
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prevent its binding to (EPOR)2. Remarkably, however, a number of these modified EPO
molecules retain potent tissue protective properties.102 Using this approach, a number of
EPO derivatives can be synthesized that are cytoprotective but are devoid of hematopoietic,
procoagulant, and vasoconstrictive activities. Carbamoylated EPO (CEPO) is one
extensively studied derivative that is produced by chemically converting the positively
charged lysines within the molecule (EPO has 8) into the neutral amino acid homocitrulline.
Erythropoietin and CEPO differ markedly in a number of biological properties. For
example, although both recruit endothelial progenitor cells, only EPO stimulates the mitosis
of more differentiated endothelial cells.107 Carbamoylated EPO has been extensively
evaluated in multiple preclinical models in our laboratory54,102,107–110 as well as by
others66,111–115 and confirmed to possess fully preserved tissue protective properties. For
example, rodent cardiomyocytes undergo apoptosis when exposed to the toxin staurosporine
in vitro. Inclusion of either CEPO or EPO in the exposure medium significantly attenuates
this apoptosis (Fig. 3). Carbamoylated EPO is currently in clinical development for ischemic
stroke (NCT00870844) and Friedreich’s ataxia (NCT01016366).
Clearly, the observation of different biological effects of EPO and CEPO support the
concept of receptor isoforms. As previously noted, the TPR is pharmacologically distinct
from (EPOR)2. Specifically, it exhibits a lower affinity for EPO, forms distinct molecular
species in cross-linking experiments,3 and when immunoprecipitated under nonreducing
conditions, the EPOR monomer is covalently bound to the βCR (CD131). Previous work has
shown that CD131 form complexes with EPOR116 and with the alpha receptor subunits
specific for granulocyte macrophage colony-stimulating factor, IL-3, and IL-5. However,
because normal hematopoiesis occurs in CD131 knockout mice, it was concluded that this
association was not biologically relevant. Thus, there are 2 different EPOR complexes, one
accounting for its hematopoietic and the other for its tissue-protective activities. As
expected, in CD131 knockout mice, neither EPO nor CEPO is tissue protective. For
example, Figure 4 shows that while wild-type mice respond well to CEPO in the setting of
spinal cord injury, neither EPO nor CEPO is protective in CD131 knockout mice.
In an effort to further characterize the structure-activity relationships of EPO, our team
produced a series of peptides based on the primary sequence of EPO as well as peptides
designed to mimic its 3-dimensional spatial structure. The most interesting peptides are
derived from residues of EPO that are not involved in binding to the classical (EPOR)2
complex (ie, regions of EPO other than sites 1 and 2; Fig. 2). These peptides were then
assayed for tissue/neuroprotective and hematopoeitic potency. As a result of these studies,
helix B was identified as a tissue protective region of EPO. Of note, helix B does not contain
lysine so it is not modified by carbamoylation. It is the only helix not involved with binding
to the homodimeric receptor.
One of the peptides, ARA 290, is currently in clinical development by Araim
Pharmaceuticals, a spin-off of Warren Pharmaceuticals. ARA 290 is a remarkable 11 amino
acid peptide composed of the spatially adjacent amino acids on the portion of helix B that
faces outward into the aqueous medium (Fig. 5). ARA 290 was designed to mimic the
tertiary structure of helix B117 and thus acts as a ligand for the TPR. Despite the fact that
ARA 290 has a short half-life (~2 minutes), it is at least equipotent on a molar basis to
rhEPO, because like asialoEPO,101 it has a rapid effect on gene expression and, in this way,
triggers protection responses.118 The tissue protective effects of ARA 290 have
demonstrated using a large number of animal models, including models of sciatic nerve
injury, middle cerebral artery ischemia, renal ischemia-reperfusion injury, and wound
healing.117 For example, in mice subjected to 30 minutes of ischemia followed by
reperfusion, administration of ARA 290 after reperfusion is associated with preservation of
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function (Fig. 6) and a reduction of tissue injury.117 In addition, like EPO, ARA 290 also
has positive effects in some normal tissues, for example, effects on cognition.
SAFETY OF ARA 290
Extensive preclinical safety studies have been carried out by Araim Pharmaceuticals. The
results of these studies show that ARA 290 even at very high dosages has no effect on
hematopoiesis or any toxic activities in rabbits, rats, or mice. Safety trials have been carried
successfully through phase 1a and 1b. ARA 290 is currently poised to enter proof-of-
concept studies.
CONCLUSIONS
Erythropoietin locally produced in response to cellular stress plays many roles in the
prevention, attenuation, and termination of injury. Erythropoietin also promotes healing and
restoration of function in diverse tissues. However, the strong suppressive effects of
proinflammatory cytokines produced by activation of the innate immune response tend to
limit the beneficial effects of locally produced EPO. In contrast, the TPR is strongly up-
regulated in the vicinity of injury, providing the rationale for systemic exogenous EPO
administration. Tissue protection requires a high local concentration of EPO because of the
relatively low affinity of the TPR. Engineered molecules that bind only to TPR avoid
hematopoietic complications and appear well suited for translation of EPO-mediated tissue
protection into the clinic.
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Erythropoietin signals via 2 distinct receptor isoforms. The hematopoietic receptor is a high
affinity homodimer that mediates hematological and vascular effects. In contrast, current
evidence suggests that the TPR is a lower affinity heteromer composed of EPOR and βCR
(CD131).
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Erythropoietin binds to (EPOR)2 by bridging across an assembled homodimer. Helices A–D
of EPO associate via hydrophobic interactions to form a compact, globular configuration.
Sites 1 and 2 (indicated by dashed boxes) within the topography of the EPO molecule bind
with high affinity to localized regions on each EPOR monomer. The aqueous face of the
helix B is oriented away from the interior of the receptor, indicated by the dashed ellipse.
Reprinted with permission from Proc Natl Acad Sci U S A.117
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The nonhematopoietic derivative carbamoylated EPO protects cardiomyocytes from
staurosporine-induced apoptosis in vitro. Mean percentage of myocytes having undergone
apoptosis after isolation from rat or mouse hearts. Shown are data for rat control (n = 9), S
(Staurosporine, n = 10), rat S plus C (S plus CEPO, n = 10), mouse S plus C (n = 4), and
mouse S plus E (S plus EPO; n = 4). *, P < 0.05; **, P < 0.01 versus staurosporine.
Reprinted with permission from Proc Natl Acad Sci U S A.54
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βCR knockout mice subjected to spinal cord compressive injury do not respond to either
rhEPO or CEPO. Normal or CD131 knockout male mice of 8 to 16 weeks of age received a
moderate compressive lesion of the spinal cord, followed immediately by a single
intraperitoneal dose of rhEPO or CEPO (10 μg/kg of body weight: the equivalent of 1000 IU
of EPO) and were subsequently evaluated for motor function for 6 weeks. Mortality was
similar between groups (≈10%–20%). Wild-type mice responded to CEPO with a complete
recovery within 4 weeks. In contrast, βcR knockout animals exhibited little recovery in
motor function among the CEPO, rhEPO, or saline groups after 6 weeks.4 Reprinted with
permission from Proc Natl Acad Sci U S A.4
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ARA 290 was synthesized based on the linear sequence of helix B indicated by the dashed
ellipse in Figure 2 (boxed region; single letter amino acid code; U: pyroglutamate). Circled
residues show those amino acid residues on the aqueous face of helix B and a linear peptide
comprising only these residues was manufactured. Reprinted with permission from Proc
Natl Acad Sci U S A.117
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ARA 290 improves renal ischemia-reperfusion injury. Renal function was assessed by
measuring plasma creatinine in mice (n = 12 each group) 24 hours after being subjected to
sham operation or renal ischemia–reperfusion injury (bilateral renal pedicle occlusion for 30
min). Phosphate-buffered saline (PBS) or ARA 290 (8.0 nmol/kg of body weight) was
administered intraperitoneally 1 minute, 6 hours, and 12 hours into reperfusion. Data
represent mean and SEM; ***, P < 0.001 versus PBS. Reprinted with permission from Proc
Natl Acad Sci U S A.117
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TABLE 1
Hematopoeitic and Neuroprotective Activities of rhEPO and Its Derivatives
rhEPO Derivative
Hematopoeitic Activities (pM)




(IC50) UT7 Proliferation† (EC50) % Neurons Protected‡
% P19 Cells
Protected§
Wild-type rhEPO 10 10–30 78 ± 13 49 ± 12
Asialo-rhEPO¶ 14 10–30 71 ± 15 n.d.
Carbamoylated rhEPO (CEPO)|| > 10,000 > 10,000 70 ± 9 49 ± 10
Asialo-CEPO > 10,000 > 10,000 69 ± 16 not done
S100E-rhEPO** 100 > 10,000 66 ± 9 55 ± 15
R103E-rhEPO†† > 10,000 > 10,000 55 ± 13 not done
*
Inhibition of rhEPO binding to (EPOR)2.
†
UT7 is an EPO-sensitive leukemic cell line.
‡
Percent rat hippocampal neurons protected after induction of apoptosis with the neurotoxin N-methyl-D-aspartate.
§
Percent P19 (neuronal precursor cells derived from murine teratocarcinoma cells) protected after induction of apoptosis by serum withdrawal.
¶
Asialo-rhEPO was generated by total enzymatic desialylation of rhEPO, possesses a very short plasma half-life and is fully neuroprotective in
vivo.
||
Carbamoylated EPO is a chemically modified rhEPO in which all of the lysines were transformed to homocitrulline by carbamoylation.
**
S100E-rhEPO is a mutein of EPO in which the S100 is changed to E100. Amino acid 100 is within site 2 (Fig. 2).
††
R103E-rhEPO is a mutein of rhEPO in which the R103 is changed to E103.
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